Screener
Gilead Sciences GILD Odefsey — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions) | Three Months Ended June 30, 2026 / U.S. | Three Months Ended June 30, 2026 / Europe | Three Months Ended June 30, 2026 / Rest of World | Three Months Ended June 30, 2026 / Total | Three Months Ended June 30, 2025 / U.S. | Three Months Ended June 30, 2025 / Europe | Three Months Ended June 30, 2025 / Rest of World | Three Months Ended June 30, 2025 / Total |
|---|---|---|---|---|---|---|---|---|
| Biktarvy | $2,981 | $468 | $323 | $3,772 | $2,799 | $429 | $302 | $3,530 |
| Descovy | 921 | 23 | 23 | 967 | 601 | 24 | 28 | 653 |
| Genvoya | 236 | 37 | 16 | 289 | 322 | 40 | 16 | 377 |
| Odefsey | 171 | 58 | 10 | 239 | 221 | 66 | 11 | 298 |
| Symtuza - Revenue share(1) | 105 | 30 | 3 | 138 | 88 | 33 | 3 | 124 |
| Yeztugo | 223 | — | 9 | 232 | 15 | — | — | 15 |
| Other HIV(2) | 23 | 24 | 10 | 56 | 50 | 33 | 9 | 92 |
| Total HIV | 4,659 | 640 | 393 | 5,693 | 4,096 | 624 | 368 | 5,088 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's odefsey — total revenues?
- Gilead Sciences (GILD) reported odefsey — total revenues of $239M in Q2 2026.
- How has Gilead Sciences's odefsey — total revenues changed year-over-year?
- Gilead Sciences's odefsey — total revenues decreased by 19.8% year-over-year, from $298M to $239M.
- What is the long-term trend for Gilead Sciences's odefsey — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's odefsey — total revenues has grown at a -7.1% compound annual growth rate (CAGR), from $1.57B to $1.17B.
- What does odefsey — total revenues mean?
- This metric represents the total gross sales generated from a specific pharmaceutical product line within the company's HIV treatment portfolio. It reflects the market demand, pricing power, and competitive positioning of this specific therapeutic asset. Tracking this revenue stream is essential for assessing the lifecycle maturity and contribution of the product to the overall infectious disease franchise.
Ask your AI about Gilead Sciences's odefsey — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude